CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 52 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2019. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,517,601 | -17.7% | 164,157 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $5,488,144 | -7.6% | 161,749 | -2.0% | 0.00% | 0.0% |
| Q1 2023 | $5,939,147 | -21.1% | 165,068 | -2.3% | 0.00% | -50.0% |
| Q4 2022 | $7,531,840 | +64.6% | 168,989 | +3.8% | 0.00% | +100.0% |
| Q3 2022 | $4,575,000 | +13.4% | 162,782 | +8.8% | 0.00% | 0.0% |
| Q2 2022 | $4,033,000 | -23.0% | 149,585 | -2.7% | 0.00% | 0.0% |
| Q1 2022 | $5,236,000 | -11.7% | 153,703 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $5,930,000 | -36.4% | 153,460 | -11.2% | 0.00% | -50.0% |
| Q3 2021 | $9,327,000 | +139.5% | 172,746 | +48.4% | 0.00% | +100.0% |
| Q2 2021 | $3,894,000 | +283.6% | 116,435 | +136.4% | 0.00% | – |
| Q1 2021 | $1,015,000 | +12.4% | 49,253 | -4.4% | 0.00% | – |
| Q4 2020 | $903,000 | +222.5% | 51,538 | +173.4% | 0.00% | – |
| Q3 2020 | $280,000 | +122.2% | 18,849 | -26.1% | 0.00% | – |
| Q1 2019 | $126,000 | – | 25,521 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 761,398 | $41,108,000 | 10.12% |
| Opaleye Management Inc. | 985,000 | $53,045,000 | 9.91% |
| VR Adviser, LLC | 1,098,174 | $59,290,000 | 7.62% |
| ACUTA CAPITAL PARTNERS, LLC | 337,500 | $18,222,000 | 6.43% |
| TSP Capital Management Group, LLC | 271,429 | $14,654,000 | 5.00% |
| Ghost Tree Capital, LLC | 255,000 | $13,767,000 | 4.03% |
| COMMODORE CAPITAL LP | 248,207 | $13,401,000 | 3.53% |
| RTW INVESTMENTS, LP | 3,908,947 | $211,044,000 | 3.18% |
| Ikarian Capital, LLC | 791,600 | $42,741,000 | 3.01% |
| Redmile Group, LLC | 3,043,298 | $164,308,000 | 2.87% |